How to buy Smith-and-Nephew shares | 1534.5p

Own Smith-and-Nephew shares in just a few minutes. Share price changes are updated daily.

Fact checked

Smith & Nephew plc (SN) is a leading medical devices business based in the UK. It opened the day at 1547.5p after a previous close of 1532.5p. During the day the price has varied from a low of 1527p to a high of 1568.7856p. The latest price was 1534.5p (25 minute delay). Smith-and-Nephew is listed on the London Stock Exchange (LSE) and employs 17,500 staff. All prices are listed in pence sterling.

How to buy shares in Smith-and-Nephew

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SN in this case.
  5. Research Smith-and-Nephew shares. The platform should provide the latest information available.
  6. Buy your Smith-and-Nephew shares. It's that simple.
The whole process can take as little as 15 minutes.

How has Coronavirus impacted Smith-and-Nephew's share price?

Since the stock market crash in March caused by coronavirus, Smith-and-Nephew's share price has had significant negative movement.

Its last market close was 1505.5p, which is 21.75% down on its pre-crash value of 1924p and 42.70% up on the lowest point reached during the March crash when the shares fell as low as 1055.005p.

If you had bought £1,000 worth of Smith-and-Nephew shares at the start of February 2020, those shares would have been worth £665.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £821.10.

Smith-and-Nephew share price

Use our graph to track the performance of SN stocks over time.

Smith-and-Nephew shares at a glance

Information last updated 2020-12-18.
Open1547.5p
High1568.7856p
Low1527p
Close1534.5p
Previous close1532.5p
Change 2p
Change % 0.131%
Volume 2,370,259
Information last updated 2020-12-27.
52-week range1033.2897p - 1939.7351p
50-day moving average 1503.3677p
200-day moving average 1526.824p
Wall St. target price18.49p
PE ratio 34.204
Dividend yield 0.3p (1.95%)
Earnings per share (TTM) 44.6p
Promoted
eToro Free Stocks

Invest in Smith-and-Nephew shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Smith-and-Nephew stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Smith-and-Nephew price performance over time

Historical closes compared with the last close of 1534.5p

1 month (2020-12-22) -1.41%
3 months (2020-10-22) 5.39%
6 months (2020-07-22) -6.09%

Is Smith-and-Nephew under- or over-valued?

Valuing Smith-and-Nephew stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Smith-and-Nephew's P/E ratio

Smith-and-Nephew's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Smith-and-Nephew shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Smith-and-Nephew's PEG ratio

Smith-and-Nephew's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5075. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Smith-and-Nephew's EBITDA

Smith-and-Nephew's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £957 million.

The EBITDA is a measure of a Smith-and-Nephew's overall financial performance and is widely used to measure a its profitability.

Smith-and-Nephew financials

Revenue TTM £4.7 billion
Operating margin TTM 11.33%
Gross profit TTM £3.8 billion
Return on assets TTM 3.59%
Return on equity TTM 7.89%
Profit margin 8.34%
Book value 5.704p
Market capitalisation £13.4 billion

TTM: trailing 12 months

Smith-and-Nephew's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Smith-and-Nephew.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Smith-and-Nephew's total ESG risk score

Total ESG risk: 33.11

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Smith-and-Nephew's overall score of 33.11 (as at 01/01/2019) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Smith-and-Nephew is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Smith-and-Nephew's environmental score

Environmental score: 4.38/100

Smith-and-Nephew's environmental score of 4.38 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Smith-and-Nephew is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Smith-and-Nephew's social score

Social score: 20.04/100

Smith-and-Nephew's social score of 20.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Smith-and-Nephew is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Smith-and-Nephew's governance score

Governance score: 9.18/100

Smith-and-Nephew's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Smith-and-Nephew is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Smith-and-Nephew's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Smith-and-Nephew scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Smith-and-Nephew has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Smith & Nephew plc was last rated for ESG on: 2019-01-01.

Total ESG score 33.11
Total ESG percentile 55.04
Environmental score 4.38
Environmental score percentile 5
Social score 20.04
Social score percentile 5
Governance score 9.18
Governance score percentile 5
Level of controversy 2

Smith-and-Nephew share dividends

83%

Dividend payout ratio: 83.45% of net profits

Recently Smith-and-Nephew has paid out, on average, around 83.45% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.95% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew shareholders could enjoy a 1.95% return on their shares, in the form of dividend payments. In Smith-and-Nephew's case, that would currently equate to about 0.3p per share.

Smith-and-Nephew's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 1 October 2020 (the "ex-dividend date").

Have Smith-and-Nephew's shares ever split?

Smith-and-Nephew's shares were split on a 9:11 basis on 7 August 2000. So if you had owned 11 shares the day before before the split, the next day you'd have owned 9 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew shares – just the quantity. However, indirectly, the new 22.2% higher share price could have impacted the market appetite for Smith-and-Nephew shares which in turn could have impacted Smith-and-Nephew's share price.

Smith-and-Nephew share price volatility

Over the last 12 months, Smith-and-Nephew's shares have ranged in value from as little as 1033.2897p up to 1939.7351p. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Smith-and-Nephew's is 0.3721. This would suggest that Smith-and-Nephew's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Smith-and-Nephew overview

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site